The Leukemia & Lymphoma Society (LLS), headquartered in the United States, is a leading non-profit organisation dedicated to funding research and providing support for patients affected by blood cancers, including leukemia, lymphoma, and myeloma. Founded in 1949, LLS has made significant strides in advancing treatments and improving patient outcomes, with notable milestones such as the development of targeted therapies and immunotherapies. Operating across major regions in the US, LLS offers a range of core services, including patient education, financial assistance, and advocacy for blood cancer research funding. What sets LLS apart is its commitment to investing in innovative research and its comprehensive support network for patients and families. With a strong market position, LLS has raised billions for research and has played a pivotal role in increasing survival rates for blood cancer patients, making it a vital resource in the fight against these diseases.
How does LLS (Leukemia & Lymphoma Society)'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Membership Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
LLS (Leukemia & Lymphoma Society)'s score of 20 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
The Leukemia & Lymphoma Society (LLS), headquartered in the US, currently does not have publicly available data regarding its carbon emissions or specific climate commitments. As such, there are no reported figures for emissions in kg CO2e, nor are there defined reduction targets or initiatives outlined in their sustainability strategy. In the absence of specific emissions data, it is important to note that many organisations in the healthcare and non-profit sectors are increasingly recognising the importance of addressing climate change and its impact on public health. While LLS has not disclosed its own commitments or targets, the broader industry context suggests a growing trend towards sustainability and carbon footprint reduction. For organisations like LLS, engaging in climate action can involve setting science-based targets, improving operational efficiencies, and promoting awareness of environmental issues within their communities. As the landscape of climate commitments evolves, it will be essential for LLS to consider how it can contribute to these efforts in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
LLS (Leukemia & Lymphoma Society) is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.